Findings

What do systematic reviews say?

537 questions · 588 findings · 23 reviews · Oral medicine and oral cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 62 · 10.5%GRADE not reported 412 · 70.1%Very low 69 · 11.7%Low 30 · 5.1%Moderate 14 · 2.4%High 1 · 0.2%

CMC/sorbitol pre-moistened swabs vs Lemon glycerin swabs

Patient preference · Adults seeking treatment for the symptom of dry mouth (xerostomia) due to any cause (e.g. medication, Sjogren's syndrome, radiotherapy,…

1 finding from 1 review

Interventions for the management of dry mouth: topical therapies 2011 · Cochrane All outcomes
Patient preference favoured CMC/sorbitol (Chi2 10.89, df=1; P = 0.001).
1 study · 20 participants
GRADE not reported

Prophylactic aciclovir (oral or intravenous) vs Prophylactic valaciclovir (oral)

Presence/absence of HSV oral lesions · Patients being treated for cancer (predominantly haematological malignancies)

Prophylactic aciclovir (oral or intravenous) showed no clear difference in presence/absence of HSV oral lesions compared with prophylactic valaciclovir (oral); GRADE not reported.

1 finding from 1 review

Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
RR 0.78 [0.26, 2.38]
2 studies · 181 participants
GRADE not reported

Prophylactic aciclovir (oral or intravenous) vs placebo

Presence/absence of HSV oral lesions · Patients being treated for cancer (predominantly haematological malignancies)

Prophylactic aciclovir (oral or intravenous) led to lower presence/absence of HSV oral lesions compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
RR 0.16 [0.08, 0.31]
9 studies · 398 participants
GRADE not reported

Prednisone vs placebo

Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Prednisone showed no clear difference in oral mucositis (any severity) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 1.03 [0.85, 1.24]
1 study · 66 participants
GRADE not reported

Prednisone vs placebo

Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Prednisone showed no clear difference in oral mucositis (severe) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.64 [0.17, 2.45]
1 study · 66 participants
GRADE not reported

Prednisone vs placebo

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Prednisone showed no clear difference in oral mucositis (moderate to severe) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.71 [0.47, 1.07]
1 study · 66 participants
GRADE not reported

Polaprezinc vs Azulene oral rinse

Salivary flow rate · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
No data on salivary flow rates were reported.
0 studies
No studies found

Polaprezinc vs Azulene oral rinse

Side effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
No data on adverse events were reported.
0 studies
No studies found

Polaprezinc vs Azulene oral rinse

Survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
Tumour response by RECIST criteria reported for a specific group of patients only; no usable survival data (Watanabe 2010)
1 study
GRADE not reported

Polaprezinc vs Azulene oral rinse

Taste disturbance (severe, > 2 on 0-3 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Polaprezinc led to lower taste disturbance (severe, > 2 on 0-3 scale) compared with azulene oral rinse; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
Over RT period
RR 0.12 [0.02, 0.83]
1 study · 31 participants
GRADE not reported

Polaprezinc vs Azulene oral rinse

Xerostomia (severe) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Polaprezinc led to lower xerostomia (severe) compared with azulene oral rinse; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
End of RT
RR 0.17 [0.04, 0.65]
1 study · 31 participants
GRADE not reported

Polaprezinc vs Azulene oral rinse

Oral pain · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Polaprezinc led to lower oral pain (severe, > 2 on 0-3 scale) compared with azulene oral rinse; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
Over RT period
RR 0.36 [0.17, 0.77]
1 study · 31 participants
GRADE not reported

Polaprezinc vs Azulene oral rinse

Disability of oral intake · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Polaprezinc showed no clear difference in disability of oral intake compared with azulene oral rinse; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
Over RT period
RR 0.31 [0.07, 1.31]
1 study · 31 participants
GRADE not reported

Polaprezinc vs Azulene

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Polaprezinc led to lower oral mucositis (moderate to severe) compared with azulene; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.43 [0.22, 0.84]
1 study · 31 participants
GRADE not reported

Polaprezinc vs Azulene

Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Polaprezinc showed no clear difference in oral mucositis (any severity) compared with azulene; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.82 [0.63, 1.06]
1 study · 31 participants
GRADE not reported

Polaprezinc vs Azulene

Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Polaprezinc led to lower oral mucositis (severe) compared with azulene; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.09 [0.01, 0.65]
1 study · 31 participants
GRADE not reported

Oral prednisone plus curcuminoids (adjunctive) vs Oral prednisone plus placebo

Reduction in pain · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment

1 finding from 1 review

Interventions for treating oral lichen planus: corticosteroid therapies 2020 · Cochrane All outcomes
Chainani-Wu 2007: no difference between adjunctive curcuminoids and placebo (recruitment stopped after interim analysis)
1 study · 28 participants
GRADE not reported

Integrated Chinese and Western medicine (incl. oral prednisone) vs Western medicine (incl. oral prednisone)

Clinical score · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment

1 finding from 1 review

Interventions for treating oral lichen planus: corticosteroid therapies 2020 · Cochrane All outcomes
Xu 2002: benefit favouring integrated Chinese and Western medicine, just attained statistical significance (very low-certainty; high risk of bias)
1 study
Very low

Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs placebo

Time to resolution of first ulcer (days) · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

Prednisone (oral, commencing 25 mg with phased dose reduction over 2… led to lower time to resolution of first ulcer (days) compared with placebo; GRADE not reported.

1 finding from 1 review

Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes
2 months
MD -6.35 [-6.74, -5.96]
1 study · 40 participants
GRADE not reported

Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs Montelukast (leukotriene receptor antagonist)

Time to resolution of first ulcer (days) · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

Prednisone (oral, commencing 25 mg with phased dose reduction over 2… led to lower time to resolution of first ulcer (days) compared with montelukast (leukotriene receptor antagonist); GRADE not reported.

1 finding from 1 review

Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes
2 months
MD -2.40 [-2.76, -2.04]
1 study · 40 participants
GRADE not reported